CA2999523A1 - Combination therapy of bromodomain inhibitors and checkpoint blockade - Google Patents
Combination therapy of bromodomain inhibitors and checkpoint blockade Download PDFInfo
- Publication number
- CA2999523A1 CA2999523A1 CA2999523A CA2999523A CA2999523A1 CA 2999523 A1 CA2999523 A1 CA 2999523A1 CA 2999523 A CA2999523 A CA 2999523A CA 2999523 A CA2999523 A CA 2999523A CA 2999523 A1 CA2999523 A1 CA 2999523A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- protecting group
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236280P | 2015-10-02 | 2015-10-02 | |
| US62/236,280 | 2015-10-02 | ||
| PCT/US2016/054924 WO2017059319A2 (en) | 2015-10-02 | 2016-09-30 | Combination therapy of bromodomain inhibitors and checkpoint blockade |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2999523A1 true CA2999523A1 (en) | 2017-04-06 |
Family
ID=57137298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2999523A Abandoned CA2999523A1 (en) | 2015-10-02 | 2016-09-30 | Combination therapy of bromodomain inhibitors and checkpoint blockade |
Country Status (16)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX349137B (es) * | 2005-06-08 | 2017-07-13 | Dana-Farber Cancer Inst | Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1). |
| CA2723114C (en) | 2008-05-16 | 2018-02-27 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| ES2561599T3 (es) | 2008-08-28 | 2016-02-29 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC |
| BR122014024883A2 (pt) | 2010-05-14 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Compostos no tratamento de neoplasia |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| CN114645015A (zh) | 2012-07-20 | 2022-06-21 | 泰加生物工艺学公司 | 造血区室的增强的重建和自动重建 |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| MX377534B (es) | 2014-02-28 | 2025-03-10 | Tensha Therapeutics Inc | Compuestos para usarse en el tratamiento de hiperinsulinemia. |
| US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| CA3024508A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| JP6799683B2 (ja) | 2016-12-02 | 2020-12-16 | タイガ バイオテクノロジーズ，インク． | ナノ粒子製剤 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN109232440B (zh) | 2018-01-16 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| US12187686B2 (en) * | 2018-09-07 | 2025-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-JAK2 inhibitors |
| TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療三陰性乳癌之組合療法 |
| KR20250167680A (ko) | 2018-11-30 | 2025-12-01 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN109666723B (zh) * | 2019-01-22 | 2022-04-15 | 南通大学 | 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用 |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| US12370217B2 (en) | 2019-05-14 | 2025-07-29 | Htyr Acquisition Llc | Compositions and methods for treating T cell exhaustion |
| WO2021011634A1 (en) * | 2019-07-15 | 2021-01-21 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| JP7502811B2 (ja) * | 2019-11-05 | 2024-06-19 | レスバーロジックス コーポレイション | Ｂｅｔブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体２阻害物質の組み合わせで主要な心血管有害事象（ｍａｃｅ）を処置および／または予防する方法 |
| JP7483032B2 (ja) * | 2019-11-26 | 2024-05-14 | ベノビオ カンパニー リミテッド | 新規ケルセチンレドックス誘導体及びｂｅｔ阻害剤としての用途 |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| JP2024503300A (ja) | 2020-12-30 | 2024-01-25 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺 |
| AU2022378630A1 (en) | 2021-10-29 | 2024-05-09 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ599258A (en) * | 2009-11-05 | 2014-05-30 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| BR122014024883A2 (pt) * | 2010-05-14 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Compostos no tratamento de neoplasia |
| US9301962B2 (en) * | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| WO2012075456A1 (en) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| HK1212345A1 (en) * | 2013-02-22 | 2016-06-10 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| CA2901799A1 (en) * | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases |
| JP2016519672A (ja) * | 2013-03-15 | 2016-07-07 | ジェネンテック， インコーポレイテッド | ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| EP3030242A1 (en) * | 2013-08-06 | 2016-06-15 | Oncoethix GmbH | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| EP3054966A4 (en) * | 2013-10-11 | 2017-04-19 | Genentech, Inc. | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy |
| EA032469B1 (ru) * | 2013-12-24 | 2019-05-31 | Бристол-Маерс Сквибб Компани | Новые трициклические соединения в качестве противораковых средств |
-
2016
- 2016-09-30 KR KR1020187012018A patent/KR20180081507A/ko not_active Withdrawn
- 2016-09-30 BR BR112018006689A patent/BR112018006689A2/pt not_active IP Right Cessation
- 2016-09-30 US US15/764,131 patent/US20190192532A1/en not_active Abandoned
- 2016-09-30 PE PE2018000491A patent/PE20181068A1/es unknown
- 2016-09-30 MA MA043037A patent/MA43037A/fr unknown
- 2016-09-30 HK HK18115329.0A patent/HK1256269A1/zh unknown
- 2016-09-30 JP JP2018517255A patent/JP2018530554A/ja active Pending
- 2016-09-30 EP EP16781957.2A patent/EP3355922A2/en not_active Withdrawn
- 2016-09-30 MX MX2018003824A patent/MX2018003824A/es unknown
- 2016-09-30 CN CN201680070462.8A patent/CN108289957A/zh active Pending
- 2016-09-30 AU AU2016331190A patent/AU2016331190A1/en not_active Abandoned
- 2016-09-30 CA CA2999523A patent/CA2999523A1/en not_active Abandoned
- 2016-09-30 WO PCT/US2016/054924 patent/WO2017059319A2/en not_active Ceased
- 2016-09-30 AR ARP160103015A patent/AR107500A1/es unknown
-
2018
- 2018-03-19 IL IL258212A patent/IL258212A/en unknown
- 2018-04-02 CL CL2018000853A patent/CL2018000853A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190192532A1 (en) | 2019-06-27 |
| MA43037A (fr) | 2018-08-08 |
| EP3355922A2 (en) | 2018-08-08 |
| AU2016331190A1 (en) | 2018-04-12 |
| PE20181068A1 (es) | 2018-07-04 |
| JP2018530554A (ja) | 2018-10-18 |
| MX2018003824A (es) | 2019-04-01 |
| KR20180081507A (ko) | 2018-07-16 |
| AR107500A1 (es) | 2018-05-09 |
| CL2018000853A1 (es) | 2018-08-31 |
| WO2017059319A3 (en) | 2017-10-12 |
| WO2017059319A2 (en) | 2017-04-06 |
| HK1256269A1 (zh) | 2019-09-20 |
| CN108289957A (zh) | 2018-07-17 |
| BR112018006689A2 (pt) | 2018-10-09 |
| IL258212A (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2999523A1 (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
| US11932625B2 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| US11236082B2 (en) | EZH2 inhibitors and uses thereof | |
| JP2011530596A (ja) | ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 | |
| WO2017139414A1 (en) | Inhibitor of indoleamine-2,3-dioxygenase (ido) | |
| JP2019518006A (ja) | Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ | |
| US20220372017A1 (en) | Hck degraders and uses thereof | |
| KR20230057350A (ko) | 스테이플화된 펩티드 및 이의 방법 | |
| KR20220098732A (ko) | 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체 | |
| US20210267973A1 (en) | Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer | |
| US20220242872A1 (en) | E3 ligase binders and uses thereof | |
| EP3814365B1 (en) | Dot1l degrader and uses thereof | |
| US20230382865A1 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| WO2024220676A1 (en) | Mrna degraders and methods of use thereof | |
| AU2020205665C1 (en) | DOT1L degraders and uses thereof | |
| US20210260033A1 (en) | Combined therapy with icos binding proteins and argininemethyltransferase inhibitors | |
| US20190350931A1 (en) | Combination therapy | |
| US20250346943A1 (en) | DEGRADER COMPOUNDS OF QSOX1 mRNA | |
| HK1161718A (en) | Halofuginone analogs for inhibition of trna synthetases and uses thereof | |
| WO2017151625A1 (en) | 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20221222 |
|
| FZDE | Discontinued |
Effective date: 20221222 |